Soy Protein Influences Insulin Sensitivity and Cardiovascular Risk in Male Lean SHHF Rats

J. Davis; J. Steinle; D. A. Higginbotham; J. Oitker; R. G. Peterson; W. J. Banz

doi:10.1055/s-2005-861475

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2005; 37(5): 309-315
DOI: 10.1055/s-2005-861475

Original Clinical

Soy Protein Influences Insulin Sensitivity and Cardiovascular Risk in Male Lean SHHF Rats

J. Davis^1, ² , J. Steinle² , D. A. Higginbotham^1, ² , J. Oitker² , R. G. Peterson³ , W. J. Banz^1, ²

¹Animal Science, Food & Nutrition, Southern Illinois University, Carbondale, IL
²Physiology, Southern Illinois University, Carbondale, IL
³Indiana University School of Medicine, Indianapolis, IN

Abstract

Previous investigations have demonstrated a marked effect of soy protein on multiple physiological parameters associated with the metabolic syndrome (MS). This preliminary study investigated the physiological effects of soy-based diets on cardiovascular risk in a unique rodent model that reflects early stages of MS. Briefly, lean male SHHF (+/cp) rats were randomly assigned to the following treatment groups: casein (control, C); low-isoflavone (LIS) soy protein isolate; high-isoflavone (HIS) soy protein isolate; or C+ 0.01 % rosiglitazone (CR). Rats were fed for thirty-six weeks. Liver weight, heart weight, total plasma cholesterol, fasting blood glucose were lower in soy-fed animals compared to control (p < 0.01). Body weight, kidney weight, alanine aminotransferase (ALT), fasting plasma insulin, and homeostasis model assessment (HOMA) score were also lower in LIS-fed rodents (p < 0.05) compared to casein treatment. All diet groups exhibited lower urine protein (p < 0.01) and small arteriole content (p < 0.05) compared to controls. LIS feed had a slightly more profound influence on body weight, liver metabolism, and insulin sensitivity. However, both soy diets exhibited marked improvements over a casein-based diet.

Key words

Soy protein - Rosiglitazone - Metabolic syndrome - Insulin - Cardiovascular disease

Full Text

References

1 Cefalu W T. Insulin resistance: cellular and clinical concepts. Experimental Biology and Metabolism. 2001; 226 13-26
2 Reaven G M. Pathophysiology of insulin resistance in human disease. Physiological Reviews. 1995; 75 473-485
3 Grundy S M, Brewer H B Jr, Cleeman J I, Smith S C , Lenfant C, American Heart Association; National Heart, Lung, and Blood Institute. Definition of Metabolic Syndrome. Circulation. 2004; 109 433-438
4 Reaven G, Abbasi F, McLaughlin T. Obesity insulin resistance, and cardiovascular disease. Recent Prog Horm Res. 2004; 59 207-223
5 Fonseca V. Effect of Thiazolidinediones on body weight in patients with Diabetes Mellitus. Am J Med. 2003; 115 42S-48S
6 Scheen A J. Thiazolidinediones and liver toxicity. Diabetes Metab.. 2001; 27 (3) 305-313
7 Setchell K DR. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr. 1998; 68 (suppl) 1333S-1346S
8 Erdman J W, Fordyce E J. Soy products and the human diet. Am J Clin Nutr. 1989; 49 724-737
9 Potter S M, Baum J A, Teng H, Stillman R J, Shay N F, Erdman J W Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal woman. Am J Clin Nutr. 1998; 68 1375S-1379S
10 Anderson J W, Johnstone B M, Cook-Newell M E. Meta-analysis of the effects of soy protein intake on serum lipids. N Eng J Med. 1995; 333 276-282
11 Baum J A, Teng H, Erdman J W, Weigel R M, Klein B P, Persky V W, Freels S, Surya P, Bakhit R M, Ramos E, Shay N F, Potter S M. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr. 1998; 68 545-551
12 Vahouny G V, Adamson I, Chalcarz W, Satchithanandam S, Muesing R, Klurfeld D M, Tepper S A, Sanghvi A, Kritchevsky D. Effects of casein and soy protein on hepatic and serum lipids and lipoprotein lipid distribution in the rat. Atherosclerosis. 1985; 56 127-137
13 Anthony M S, Clarkson T B, Williams K J. Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am J Clin Nutr. 1998; 68 1390S-1393S
14 Anthony M S, Clarkson T B, Bullock B C, Wagner J D. Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus mokeys. Atherosclerosis, Thrombosis, and Vascular Biology. 1997; 17 2524-2531
15 Maddox D A, Alavi F K, Silbernick E M, Zawada E T. Protective effects of a soy diet in preventing obesity-linked renal disease. Kidney International. 2002; 61 96-104
16 Peluso M R, Winters T A, Shanahan M F, Banz W J. A cooperative interaction between soy protein and its isoflavone-enriched fraction lowers hepatic lipids in male obese Zucker rats and reduces blood platelet sensitivity in male Sprague-Dawley rats. J Nutr. 2000; 130 2333-2342
17 Lavigne C, Marette A, Jacques H. Cod and soy proteins compared with casein improve glucose tolerance and insulin sensitivity in rats. Endocrinology and Metabolism. 2000; 278 E491-E500
18 Iritani N, Sugimoto T, Fukuda H, Komiya M, Ikeda H. Dietary soybean protein increases insulin receptor gene expression in Wistar Fatty rats when dietary polyunsaturated fatty acid level is low. J Nutr. 1997; 127 1077-1083
19 Tovar-Palacio C, Potter S M, Hafermann J C, Shay N F. Intake of soy protein and soy protein extracts influencelipid metabolism and hepatic gene expression in gerbils. J Nutr. 1998; 128 839-842
20 Dixon R A, Ferreira D. Genistein. Phytochemistry. 2002; 60 205-211
21 Crouse J R 3rd, Morgan T, Terry J G, Ellis J, Vitolins M, Burke G L. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med. 1999; 159 2070-2076
22 Sanders T A, Dean T S, Grainger D, Miller G J, Wiseman H. Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor β1 concentrations and hemostatic risk factors for coronary heart disease in healthy subjects. Am J Clin Nutr. 2002; 76 373-377
23 Fukui K, Tachibana N, Wanezaki S, Tsuzaki S, Takamatsu K, Yamamoto T, Hashimoto Y, Shimoda T. Isoflavone-free soy protein prepared by column chromatography reduces plasma cholesterol in rats. J Agric Food Chem. 2002; 50 5717-5721
24 Jenkins D J, Kendall C W, Jackson C J, Connelly P W, Parker T, Faulkner D, Vidgen E, Cunnane S C, Leiter L A, Josse R G. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. Am J Clin Nutr. 2002; 76 365-372
25 Tofovic S P, Kusaka H, Kost C K Jr, Bastacky S. Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF-hybrid rats. Ren Fail. 2000; 22 (4) 387-406
26 Hoversland R C. Onset of obesity and puberty in genetically obese SHHF/Mcc-cp rats. Int J Obes Relat Metab Disord. 1992; 16 (12) 977-984
27 Meier D A, Hennes M M, McCune S A, Kissebah A H. Effects of obesity and gender on insulin receptor expression in liver of SHHF/Mcc-FAcp rats. Obes Res. 1995; 3 (5) 465-470
28 Reeves P G, Nielsen F H, Fahey G C Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993; 123 1939-1951
29 Maddox D A, Alavi F K, Santella R N, Zawada E T Jr. Prevention of obesity-linked renal disease: age-dependent effects of dietary food restriction. Kidney Int. 2002; 62 (1) 208-219
30 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28 (7) 412-419
31 Harris R B, Martin R J. Specific depletion of body fat in parabiotic partners of tube-fed obese rats. Am J Physiol. 1984; 247 R380-R386
32 Tomanek R J, Palmer P J, Peiffer G L, Schreiber K L, Eastham C L, Marcus M L. Morphometry of canine coronary arteries, arterioles, and capillaries during hypertension and left ventricular hypertrophy. Circ Res. 1986; 58 38-46
33 Cimini C M, Weiss H R. Microvascular morphometry and perfusion in renal hypertension-induced cardiac hypertrophy. Am J Physiol. 1988; 255 H1384-H1390
34 Davis J, Higginbotham A, Iqbal J, Peterson R, Shay N, Banz W. Soy protein diets attenuate abnormalities observed in male ZDF rats. 2003 Experimental Biology meeting abstracts [accessed at http://select.biosis.org/faseb]. The FASEB Journal 18, Abstract #197.2
35 Nagasawa A, Fukui K, Funahashi T, Maeda N, Shimomura I, Kihara S, Waki M, Takamatsu K, Matsuzawa Y. Effects of soy protein diet on the expression of adipose genes and plasma adiponectin. Horm Metab Res. 2002; 34 (11 - 12) 635-639
36 Ishihara K, Oyaizu S, Fukuchi Y, Mizunoya W, Segawa K, Takahashi M, Mita Y, Fukuya Y, Fushiki T, Yasumoto K. A soybean peptide isolate diet promotes postprandial carbohydrate oxidation and energy expenditure in type II diabetic mice. J Nutr. 2003; 133 (3) 752-757
37 Saito M. Effect of soy peptides on energy metabolism in obese animals [in Japanese]. Nutr. Sci. Soy Protein. 1991; 12 91-94
38 Anderson R, Wolf W. Compositional changes in trypsin inhibitor, phytic acid, saponins, and isoflavones related to soybean processing. J Nutr. 1995; 125 581-588
39 Smith S A, Lister C A, Toseland C DN, Buckingham R E. Rosiglitazone prevents the onset of hyperglycemia and proteinuria in the Zucker Diabetic Fatty rat. Diabetes, Obesity and Metabolism. 2000; 2 363-372
40 Brown K K, Henke B R, Blanchard S G, Cobb J E, Mook R, Kaldor I, Kliewer S A, Lehmann J M, Lenhard J M, Harrington W W, Novak P J, Faison W, Binz J G, Hashim M A, Oliver W O, Brown H R, Parks D J, Plunket K D, Tong W Q, Menius J A, Adkison K, Noble S A, Willson T M. A novel n-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker Diabetic Fatty rat. Diabetes. 1999; 48 1415-1424
41 Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998; 101 1354-1361
42 Vidal-Puig A, Jimenez-Linan M, Lowell B B, Hamann A, Hu E, Spiegelman B, Flier J S, Moller D E. Regulation of PPARγ gene expression by nutrition and obesity in rodents. J Clin Invest. 1996; 97 2553-2561
43 Yakubu-Madus F E, Stephens T W, Johnson W T. Lipid lowering explains the insulin sensitivity enhancing effects of a thizolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione. Diabetes, Obesity and Metabolism. 2000; 2 155-163
44 Smith U, Cogg S, Johansson A, Olausson T, Rotter V, Svalstedt B. Thiazolidinediones (PPARγ agonists) but not PPAR α agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB. 2001; 15 215-220
45 Zierath J R, Ryder J W, Doebber T, Woods J, Wu M, Ventre J, Li Z, McCrary C, Berger J, Zhang B, Moller D E. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action. Endocrinology. 1998; 139 5034-5041
46 Berger J, Moller D E. The mechanisms of action of PPARs. Annu Rev Med. 2002; 53 409-435
47 Ricote M, Huang J T, Welch J S, Glass C K. The peroxisome proliferators-activated receptor-γ (PPARγ) as a regulator of monocyte/macrophage function. J Leukoc Biol. 1999; 66 733-739
48 Keller J M, Collet P, Bianchi A, Huin C, Bouillaud-Kremarik P, Becuwe P, Schohn H, Domenjoud L, Dauca M. Implications of peroxisome proliferators-activatedreceptors (PPARS) in development, cell life status, and disease. Int J Dev Biol. 2000; 44 429-442
49 Willson T M, Lambert M H, Kilewer S A. Peroxisome proliferator-activated receptor γ and metabolic disease. Annu Rev Biochem. 2001; 70 341-367
50 Toruner F, Akbay E, Cakir N, Sancak B, Elbeg S, Taneri F, Akturk M, Karakoc A, Ayvaz G, Arslan M. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats. Horm Metab Res. 2004; 36 (4) 226-230
51 Mezei O, Banz W J, Steger R W, Peluso M R, Winters T A, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr. 2003; 133 1238-1243
52 Jeong S K, Nam H S, Rhee J A, Shin J H, Kim J M, Cho K H. Metabolic syndrome and ALT: a community study in adult Koreans. Int J Obes Relat Metab Disord. 2004; 28 (8) 1033-1038
53 Hayashi U, Nagao K, Yshioka Y. Relationship between food containing “Natto” (fermented soybeans) and the blood pressure of SHR. Jpn Heart. J1976; 17 343-344
54 Nevala R, Vaskonen T, Vehniainen J, Korpela R, Vaatalo H. Soy based diet attenuates the development of hypertension when compared with casein based diet in spontaneously hypertensive rat. Life Sci. 2000; 66 115-124
55 Martin D S, Breitkopf N P, Eyster K M, Williams J L. Dietary soy exerts an antihypertensive effect in spontaneously hypertensive female rats. Am J Physiol Regul Integr Comp Physiol. 2001; 281 (2) R553-R560
56 Anderson J W, Johnstone C M, Cook-Newell M E. Meta-analysis of the effects of soy protein intake on serum lipids. N Eng J Med. 1995; 333 276-282
57 Umeda M, Kanda T, Murakami M. Effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats. Hypertens Res. 2003; 26 (6) 485-492
58 Smith S A, Lister C A, Toseland C D, Buckingham R E. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab. 2000; 2 (6) 363-372
59 Schiffrin E L, Amiri F, Benkirane K, Iglarz M, Diep Q N. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension. 2003; 42 (4) 664-668

William J. Banz, Ph. D., RD

Department of Animal Science, Food and Nutrition, Southern Illinois University

Carbondale, IL 62901-4317, USA

Phone: +1 (618) 453-7511

Fax: +1 (618) 453-7517

Email: banz@siu.edu